Inhibrx Biosciences financials
$104.83+3.07%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $1.3M | $200.0K |
| Gross profit | $1.3M | $200.0K |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$135.0M | -$331.4M |
| Net income | -$140.1M | $1.69B |
| Net margin | −10773.5% | 843786.0% |
| Diluted EPS | $-9.04 | $112.62 |
| EBITDA | -$132.5M | -$329.2M |
| Operating cash flow | -$129.8M | -$194.4M |
| Free cash flow | -$129.8M | -$197.0M |
| Diluted shares | 15.5M | 15.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $124.2M | $152.6M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $100.6M | $0.00 |
| Total assets | $146.5M | $180.8M |
| Total liabilities | $138.5M | $47.2M |
| Shareholders' equity | $8.0M | $133.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology